Evidence
Pharmacogenomics. 2023 May 11. doi: 10.2217/pgs-2023-0037. Online ahead of print.
ABSTRACT
Aim: To evaluate the association between OPRK1 rs963549 and rs997917 and opioid use disorder (OUD) and related phenotypes. Methods: A sample of 208 individuals with (n = 100) and without (n = 108) OUD were enrolled. OPRK1 rs963549 and rs997917 were analyzed by PCR-RFLP. Craving, opioid withdrawal and the intensity of depressive and anxiety symptoms were measured by the appropriate scales. Results: OPRK1 rs963549 variation showed a trend of association with decreased opioid withdrawal. No significant associations were found between OPRK1 rs963549 and rs997917 polymorphisms and craving, depression or anxiety symptoms. Neither single OPRK1 SNPs nor OPRK1 haplotypes were associated with OUD. Conclusion: Our results could be useful for treatment failures of individuals who experience greater opioid withdrawal due to their OPRK1 rs963549 genotypes.
PMID:37166316 | DOI:10.2217/pgs-2023-0037
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and the related phenotypes
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and the related phenotypes
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and the related phenotypes
🌐 365 Days
VR Related Evidence Matrix
